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Phosphatidylcholine is generated through de novo synthesis and remodeling involving a lysophospholipid. In
this issue of Cell Metabolism, research from the Shimizu lab (Harayama et al., 2014) demonstrates the highly
selective enzymatic behavior of lysophospholipid acyltransferases. The authors present an enzymatic model
for phosphatidylcholine molecular species diversification that impacts surfactant formation.Phosphatidylcholine (PC) is a major con-
stituent of the cellular lipidome and a fun-
damental cellular component needed to
sustain life. In mammals, PC is the primary
scaffold phospholipid of cell membranes,
an integral component of lipoproteins,
and serves as a reservoir for the generation
of critical lipid second messengers. In the
lung, PC is also the predominant consti-
tuent of surfactant, a lipoprotein complex-
like material that lines the organ’s innerFigure 1. Pathways of Surfactant Generation
Top: The de novo pathway involves the acylation of lysophosphatidic acid
catalyzed by a lysophosphatidic acid acyltransferase (LPAAT) generating
phosphatidic acid. LPAAT exhibits substrate selectivity for linoleoyl-CoA or
docosahexaenoyl-CoA (18:2 or 22:6, respectively) as acyl groups. Phospha-
tidic acid in a series of subsequent steps (data not shown) can be converted
to lysophosphatidylcholine, which lacks its sn-2-linked acyl group and in turn
can serve as a substrate for the remodeling pathway.
Bottom: In phosphatidylcholine (PC) remodeling in lung epithelia, lysophos-
phatidylcholine is reacylatedwith palmitoyl CoA through actions of a lysophos-
phatidylcholine acyltransferase (LPCAT) at the sn-2 position of the glycerol
backbone. Unlike LPAATs, LPCATs exhibit substrate selectivity for palmitoyl
CoA (or oleoyl-CoA, data not shown). This reaction generates the product
dipalmitoylphosphatidylcholine, the major surface-active component of
surfactant.surface tomaintain lowsurface
tension, thereby preventing
alveolarcollapse.Althoughde-
ficiencies, abnormal concen-
trations, or trafficking of PC
occur in several human disor-
ders (Delaunay et al., 2009;
Gadiya et al., 2014; Payne
et al., 2014), primary defici-
ency of PC within surfactant
is profoundly linked, etiolo-
gically, to the neonatal res-
piratory distress syndrome.
Indeed, PC-containing sur-
factant-replacement therapy
has revolutionized the care of
neonates with this disorder
(Polin and Carlo, 2014). How-
ever, the makeup of surfactant
phospholipid is unique, and
there exist important differ-
ences in themolecular compo-
sition of PC molecules among
cells and tissues. In this issue
of Cell Metabolism, Harayama
and colleagues provide key
insight into the pathways that
are responsible for PC mole-
cular species diversity and a
molecular model for surfactant
generation.The diverse biological roles of PC can
be attributed, in part, not only to the sub-
strate pool, or the relative mass of PC to
other phospholipids and its subcellular
compartmentalization, but also to its mo-
lecular composition. The molecular struc-
ture of PC contains a polar head group
that is covalently attached to a glycerol
backbone at the sn-3 position and two
acyl chains that are linked at the sn-1
and sn-2 positions (Figure 1). LipidomicCell Metabolism 2analysis in various systems confirms that
phospholipid molecular species are di-
verse, and their acyl chains at specific
positions are subject to enzymatic regula-
tory control (Houjou et al., 2005). In many
PC molecules, the sn-1 position contains
a saturated or shorter-chain acyl group,
whereas the sn-2 site is linked to a more
unsaturated, long-chain acyl group. How-
ever, a relatively unique feature of pul-
monary surfactant is that both sn-1 and0, August 5sn-2 positions are enriched
with saturated acyl groups,
notably palmitoyl (or less
commonly myristoyl or palmi-
toleoyl), termed disaturated or
dipalmitoyl-PC (Postle et al.,
2001). This acyl species pro-
file of surfactant PC in hu-
mans is critical to confer tight
packing of PCwith themolec-
ular monolayer as it lines the
lung surface. Thus, a major
question that has evaded in-
vestigators in the field is the
following: how is the mole-
cular signature species of PC
typical of surfactant gener-
ated? In essence, understand-
ing the enzymatic basis for PC
molecular species differences
in cells could unveil targets
for interventions to modify cel-
lular lipidomics, including sur-
factant content.
Harayama and colleagues
comprehensively examined
the enzymatic behavior of
key lysophospholipid acyl-
transferases within two path-
ways for PC generation: the
de novo and remodeling, 2014 ª2014 Elsevier Inc. 195
Cell Metabolism
Previewspathways. The de novo pathway involves
a reaction catalyzed by a lysophosphati-
dic acid acyltransferase (LPAAT) that
covalently attaches a specific acyl-CoA
group to lysophosphatidic acid gener-
ating phosphatidic acid (Figure 1). The
latter molecule is converted to diacylgly-
cerol (DAG) that reacts with cytidine di-
phosphocholine in the terminal step of
the de novo pathway to generate PC.
Hence, the ‘‘molecular fingerprint’’ of PC
species in this pathway is not only deter-
mined in a step upstream of DAG forma-
tion, but also both saturated (surfactant)
and unsaturated (nonsurfactant) PC spe-
cies are generated via this mechanism.
In a separate remodeling pathway, how-
ever, unsaturated, long-chain acyl groups
linked at the sn-2 position are cleaved by
a phospholipase A2 generating lysopho-
sphatidylcholine (Lyso-PC), which then
undergoes reacylation with a saturated
fatty acyl group. This remodeling is highly
active in the lung to enrich surfactant pro-
duction, and others have suggested that
acyl chain heterogeneity is attributed to
this pathway (MacDonald and Sprecher,
1991). The identities of the enzymes in-
volved in surfactant remodeling, an area
of significant interest, however, has eva-
ded investigators in the field for decades
until the identification of lysophospha-
tidylcholine acyltransferases (LPCATs)
(Chen et al., 2006; Nakanishi et al.,
2006). The studies by Harayama et al.
show that LPCATs display acyl-CoA
selectivity as these enzymes prefer palmi-
tate or monounsaturated acyl-CoAs as
substrates. Targeted disruption in mice
of LPCAT1, a predominant isoform in the
lung, led to reduced surfactant (dipalmi-196 Cell Metabolism 20, August 5, 2014 ª201toyl-PC) in lung fluid coupled with defects
in lung mechanics. Hence, the results
underscore the indispensability of this re-
modeling enzyme with regard to surfac-
tant generation. Quite surprisingly, the
authors show that the PC species profile
is also governed by LPAATs that utilize
polyunsaturated acyl-CoAs as substrates
such as linoleoyl- or docosahexaenoyl-
CoAs. The significance of this discovery
is that LPAATs may be critical for nonsur-
factant PC generation in some systems.
For example, LPAATs could impact neu-
robiological development or regulate the
availability of anti-inflammatory mediators
because of the significant role of docosa-
hexaenoic acid or its derivatives in medi-
ating such processes.
Future studies of mechanisms that
regulate PC molecular species will need
to address several fundamental ques-
tions. The key modes of regulation (tran-
scriptional, posttranslational, subcellular
shuttling), activation or inactivation, and
coregulators of lysophospholipid acyl-
transferases will need to be determined
and correlated with qualitative and quan-
titative changes not only in PC but also
within the greater lipidome. In addition,
the ‘‘nonlipogenic’’ behavior of some ly-
sophospholipid acyltransferases is now
being recognized and may be an area of
potential importance (Zou et al., 2011).
The biological activities of these enzymes
can be tested using in vivo gene-targeting
systems, but their roles can be further
assessed by identification of polymor-
phisms linked to human disease. The po-
tential for identifying molecular signatures
within lysophospholipid acyltransferases
that make them amenable to structure-4 Elsevier Inc.based design of small-molecule ther-
apeutics or for biomarker analysis also
remains an intriguing area for future
investigation.
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